1PASSWORD
4.6.2024 07:01:32 CEST | Business Wire | Press release
1Password, a leader in identity security, today announced significant business momentum across Europe, the Middle East, and Africa (EMEA). With a strategic focus on the region, 1Password is expanding its workforce, launching products tailored to the EMEA market, and securing over 35% of Europe’s Top 100 companies. Today, over one-third of 1Password’s B2B customers are based in EMEA.
The majority (68%) of security breaches are still caused by a human element resulting in compromised credentials, and the company recently launched 1Password Extended Access Management (XAM), an industry-first solution designed to secure every login to every app from every device, addressing the modern workforce’s need for even more seamless and secure access. Now available in the EMEA region, this solution protects users' privacy and gives businesses strong security across managed and unmanaged applications and devices, while offering visibility and insights to help them meet resilience, compliance, and audit goals. As a leading enterprise password manager, 1Password enhances identity security by providing businesses with secure access to their most sensitive information, such as login credentials and SSH keys, actionable insights to address vulnerabilities, and seamless integration with existing security infrastructure.
1Password recently hired Oliver Cheal as Vice President, EMEA. In this role, he will oversee the company’s EMEA-based teams that are focused on designing, developing, selling, and supporting 1Password’s identity and access management solutions for customers in the region. Cheal was most recently at Cisco and Duo Security and his background is in transforming cybersecurity businesses by leading organizational change and building out the go-to-market function. With more than 100 employees in EMEA, 1Password is actively investing in its EMEA workforce, with plans to open positions across sales, marketing, customer success, and partnerships in the UK, Netherlands, and Germany.
“I am thrilled to join 1Password at such a pivotal time and grow our EMEA team to better serve our customers across the region,” said Oliver Cheal, VP of EMEA. “With 1Password Extended Access Management, we're revolutionizing access management by bridging the gaps left by traditional IAM solutions. With its seamless integration and user-friendly design, we are able to empower IT and security teams with unparalleled visibility and control, ensuring their employees can safely use the tools they need, whether working remotely or in the office.”
Earlier this year, the company launched the 1Password Global Partner Program and the 1Password® Enterprise Password Manager - MSP Edition in beta to provide resellers, distributors, and Managed Service Providers (MSPs) with the tools and resources they need to help their customers become more secure. Key strategic partners in EMEA include Amazon Web Services (AWS), Arrow Electronics, Insight Enterprises, Tap.De, and SVA.
“Watching 1Password's expansion into EMEA is incredibly exciting. Their growth and vision have always perfectly aligned with ours, and we are thrilled to be part of this journey, supporting their success every step of the way. By addressing critical security gaps with their new Extended Access Management (XAM) solution, 1Password is pioneering a new category in cybersecurity that ensures comprehensive protection across the modern, hybrid work environment and we are excited to be their partner,” said Ikramul Khaled, the Group Head of Vendor Alliances at QBS Technology Group.
For more information about 1Password, visit our website here.
About 1Password
Trusted by over 150,000 businesses and millions of consumers, 1Password offers identity security and access management solutions built for the way people work and live today. 1Password is on a mission to eliminate the conflict between security and productivity while securing every sign-in for every app on every device. As the provider of the most-used enterprise password manager, 1Password continues to innovate on its strong foundation to offer security solutions relied upon by companies of all sizes, including Associated Press, Salesforce, GitLab, Under Armour, and Intercom.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240603036115/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Okomera Strengthens Its Leadership Team With the Appointment of Marion Ghibaudo as Chief Technology Officer16.9.2026 08:00:00 CEST | Press release
An expert in scaling medical innovations, Marion Ghibaudo joins Okomera as the company advances toward industrial deployment. Okomera, a TechBio company pioneering next-generation cancer care through the development of a proprietary technology platform combining tumor mini-avatars, microfluidics, and AI-powered imaging, today announced the appointment of Marion Ghibaudo as Chief Technology Officer. She will spearhead the company’s technology and innovation strategy and lead the industrial deployment of its integrated hardware, software, and biological platform. Marion Ghibaudo will join Okomera’s Executive Committee and report to CEO Silvère Lucquin. In parallel, Raphaël Tomasi, Okomera’s co-founder and former CTO, transitions to the role of VP Platform, ensuring continuity in the development of the company’s technology platform. Marion’s appointment comes at a key stage in Okomera’s growth as the company advances toward pilot studies, industrial scale-up, and commercialization. Okomer
Galderma’s Restylane® Volyme™ Demonstrates High Effectiveness, Satisfaction and a Robust Safety Profile in Chinese Patients With Temple Hollowing16.9.2026 07:00:00 CEST | Press release
Positive topline results showed that Restylane Volyme (known as Restylane Contour in the U.S.) was highly effective in the correction of moderate-to-severe temple hollowing, with high responder rates maintained through Month 121 Restylane Volyme was well tolerated, with no incidences of granulomas. Patient and investigator satisfaction were also high1 These data support Galderma’s aim to expand the availability of the Restylane portfolio in China – a market undergoing significant expansion, and further strengthen Restylane’s vast clinical evidence base2,3 Galderma (SIX: GALD) today announced positive topline results from a study of Restylane Volyme for the correction of moderate-to-severe temple hollowing in 162 patients in China.1 The study met its primary endpoint, demonstrating the effectiveness and safety of Restylane Volyme versus a no-treatment control, while also achieving high patient and investigator satisfaction.1 These data further reinforce Galderma's ambition to expand its
Nippon Electric Glass’s IR Transmitting Glass “FI-02” Adopted for Heimann Sensor Lens Unit, Enabling a 120° × 68° Field of View16.9.2026 03:00:00 CEST | Press release
Nippon Electric Glass Co., Ltd. (NEG) (TOKYO: 5214), a global leader in specialty glass headquartered in Otsu, Japan, announced that its IR Transmitting Glass (chalcogenide glass) “FI-02” has been adopted for Heimann Sensor GmbH’s wide-angle lens unit for thermal cameras. The lens unit achieves a 120° × 68° field of view, surpassing the previous product’s maximum of 92° × 59°. The adoption marks a significant milestone for FI-02 and showcases how advanced specialty glass can meet the demanding optical and manufacturing requirements of the expanding infrared sensing market. Thermal cameras detect infrared radiation emitted by people or objects and convert it into thermal images. Infrared sensors can detect the locations of people and temperature distributions. They are expected to be used for people detection and monitoring, where privacy considerations are important, and for air-conditioning control, while their use is expanding in healthcare, equipment monitoring, and security. Advanc
Workiva Advances Regulatory Work with AI Innovation15.9.2026 17:00:00 CEST | Press release
Agent Studio anchors AI capabilities unveiled at Amplify 2026 Workiva Inc. (NYSE: WK), a leading, audit-ready platform for trust, transparency, and accountability, unveiled dozens of new product and platform innovations at Amplify 2026, the company’s annual conference attended by thousands of finance, accounting, sustainability, risk, and compliance leaders. Workiva Debuts Agent Studio Workiva introduced Agent Studio, a landmark platform capability that empowers users to quickly build, customize, and deploy AI agents in Workiva's trusted platform. By combining AI reasoning with Workiva's native platform capabilities, enterprise knowledge, and governed workflows, Agent Studio enables users to automate sophisticated manual business processes without writing any code. Organizations can enrich agents with company-specific knowledge and context, tailor them to their own processes, and schedule automations to execute recurring work. “With Agent Studio, we're putting the power to build in the
Study: Heatwaves Increase Cough Urge, Which Salt Aerosols Reduce15.9.2026 15:15:00 CEST | Press release
New Study Indicates Non-Pharmacological Aerosol May Provide Therapeutic Relief for Respiratory Conditions Provoked by the Atmospheric Aridity Inherent to Heatwaves SC Therapeutics, with University North Carolina, Imperial College London, and Boston University, announced publication on Tuesday in Nature Scientific Reports of results from a multi-institutional study indicating that the aridity inherent in heatwaves increases cough hypersensitivity in human airways by collapsing mucus onto cilia in a manner common to chronic respiratory diseases, such as cystic fibrosis, and asthma. The researchers find that alkaline aerosols of magnesium salts reverse mucosal collapse for several hours, and reduce cough hypersensitivity as reflected in placebo-adjusted suppression of daily cough bout rate (59%, p=0.03) and persistence of suppression post treatment for 1 to 3 weeks in a randomized, double-blind, placebo-controlled study of 10 refractory chronic cough patients. “Paris recorded 5,764 excess
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom